Trial Profile
Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs MV NIS (Primary) ; MV NIS (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Vyriad
- 26 Jun 2023 Status changed from active, no longer recruiting to completed.
- 05 May 2023 Planned End Date changed from 1 Dec 2022 to 30 May 2023.
- 05 May 2023 Planned primary completion date changed from 1 Apr 2022 to 30 May 2023.